23:09:59 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-22 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-30 Kvartalsrapport 2024-Q1
2024-04-17 Ordinarie utdelning NANOFH 0.00 EUR
2024-04-16 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-22 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-04-13 Ordinarie utdelning NANOFH 0.00 EUR
2023-04-12 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-29 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-13 Ordinarie utdelning NANOFH 0.00 EUR
2022-04-12 Årsstämma 2022
2022-02-22 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-11-17 Extra Bolagsstämma 2021
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-27 Kvartalsrapport 2021-Q1
2021-04-07 Ordinarie utdelning NANOFH 0.00 EUR
2021-04-06 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-09-01 Extra Bolagsstämma 2020
2020-08-28 Kvartalsrapport 2020-Q2

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Nanoform Finland är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av tekniska produkter som används för att skapa nanopartiklar i läkemedel. Tekniken används som komplement i produktionsprocessen och används för behandling av sjukdomar som ALS och Alzheimers. Kunderna består av aktörer inom den globala läkemedelsindustrin. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingfors.
2022-09-06 17:00:00

Company release

Nanoform Finland Plc

September 6, 2022

06:00 p.m. Finnish time / 05:00 p.m. Swedish time

Share subscriptions based on Nanoform Finland Plc's stock options 2-3/2019 and 1/2020

Helsinki, Finland - A total of 49,000 Nanoform Finland Plc's (the "Company" or "Nanoform") new shares has been subscribed for with the Company's stock options 2/2019, 3/2019 and 1/2020 by 30 August 2022. The entire subscription price for subscriptions made with the stock options of EUR 56,100.00 will be entered in the Company's reserve for invested unrestricted equity. After the trade registration the total amount of shares is 78,363,964. The shares subscribed for under the stock options are expected to be registered in the Trade Register on or about 15 September 2022, as of which date the new shares will establish shareholder rights. The shares will be traded on the he Premier-segment of Nasdaq First North Growth Market in Helsinki together with the old shares on or about 16 September 2022.

For further information, please contact:

Peter Hänninen, General Counsel

peter.hanninen@nanoform.com

+358 50 353 040

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com

+46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.